Recombinant PTH 1-34 | Anabolic - it BUILDS bone | For severe osteoporosis | Intermittent dosing is the whole trick
WHERE IT SITS AMONG OSTEOPOROSIS DRUGS
Critical Must-Knows
- Teriparatide is recombinant human parathyroid hormone (the 1-34 amino-acid fragment) - it is the active, biologically functional N-terminal portion of PTH
- It is anabolic: given as a once-daily injection it stimulates osteoblasts and builds new bone, which is the opposite of the anti-resorptive bisphosphonates
- Intermittent versus continuous is the key concept: short daily pulses favour bone formation, whereas continuous high PTH (as in hyperparathyroidism) drives net bone resorption
- It reduces fractures: the landmark trial cut new vertebral fractures by about two-thirds, and head-to-head it beat risedronate for vertebral fracture in severe osteoporosis
- Limited to 24 months lifetime and carries a historical osteosarcoma signal from rat studies - then follow with an anti-resorptive to preserve the gains
Clinical Pearls
- "Teriparatide is the classic anabolic answer when an examiner contrasts it with bisphosphonates (anti-resorptive)
- "The 'intermittent versus continuous' PTH paradox is the favourite basic-science viva point
- "Never leave a patient on nothing after teriparatide - the bone gained is lost without a follow-on anti-resorptive
- "Avoid it where there is a high baseline osteosarcoma risk: Paget disease, prior skeletal radiotherapy, unexplained high alkaline phosphatase, open growth plates
Clinical Imaging
Severe vertebral osteoporosis - the disease teriparatide treats
Critical Teriparatide Exam Points
What It Is
Teriparatide is recombinant human parathyroid hormone, the 1-34 fragment - the active N-terminal portion of the 84-amino-acid hormone. It is given as a once-daily subcutaneous injection. This is the textbook definition examiners want first.
Anabolic Mechanism
It is the main anabolic osteoporosis drug: intermittent PTH stimulates osteoblasts, increasing bone formation more than resorption, so bone mass and architecture improve. Contrast this directly with bisphosphonates, which are anti-resorptive.
Intermittent vs Continuous
The paradox: brief daily pulses build bone, but continuously raised PTH (as in primary hyperparathyroidism) destroys bone. The same molecule has opposite effects depending on the exposure pattern - a classic viva trap.
Limits and Sequencing
Capped at 24 months lifetime with a historical osteosarcoma signal in rats. The gains are temporary, so always follow with an anti-resorptive (bisphosphonate or denosumab) to preserve the new bone.
Memory aids
BUILDWhy Teriparatide Is Special
| B | Bone-building (anabolic) Stimulates osteoblasts - opposite of bisphosphonates |
| U | Use is limited to 24 months Lifetime cap, then follow with an anti-resorptive |
| I | Intermittent daily pulses Short pulses build; continuous PTH resorbs |
| L | Lock in the gains afterwards Bisphosphonate or denosumab to preserve new bone |
| D | Daily subcutaneous injection Self-administered PTH 1-34 |
| B | Bone-building (anabolic) Stimulates osteoblasts - opposite of bisphosphonates | L | Lock in the gains afterwards Bisphosphonate or denosumab to preserve new bone |
| U | Use is limited to 24 months Lifetime cap, then follow with an anti-resorptive | D | Daily subcutaneous injection Self-administered PTH 1-34 |
| I | Intermittent daily pulses Short pulses build; continuous PTH resorbs |
Hook:Teriparatide is here to BUILD - Bone-building, Use 24 months, Intermittent pulses, Lock in the gains, Daily injection.
PROUDWhen to Avoid Teriparatide
| P | Paget disease of bone Already high bone turnover and osteosarcoma risk |
| R | Radiotherapy to the skeleton (prior) Raises baseline osteosarcoma risk |
| O | Open growth plates / young patients Skeletally immature - avoid |
| U | Unexplained high alkaline phosphatase Possible occult bone disease |
| D | Disease causing hypercalcaemia or bone metastases Including myeloma and skeletal malignancy |
| P | Paget disease of bone Already high bone turnover and osteosarcoma risk | U | Unexplained high alkaline phosphatase Possible occult bone disease |
| R | Radiotherapy to the skeleton (prior) Raises baseline osteosarcoma risk | D | Disease causing hypercalcaemia or bone metastases Including myeloma and skeletal malignancy |
| O | Open growth plates / young patients Skeletally immature - avoid |
Hook:Do not be PROUD to prescribe it here - Paget, Radiotherapy, Open physes, Unexplained high ALP, Disease with hypercalcaemia or bone cancer.
Overview
Teriparatide is the first and best-known anabolic (bone-building) drug for osteoporosis. Almost every other osteoporosis treatment is anti-resorptive - it slows the cells that break bone down. Teriparatide does the opposite: it switches on the cells that build bone up, so it can rebuild a depleted skeleton rather than simply preserving what remains.
Chemically it is recombinant human parathyroid hormone (PTH) 1-34 - the first 34 amino acids of natural PTH, which is the part that carries the hormone's activity. It is given as a once-daily subcutaneous injection for a limited period.
For the exam, three threads recur throughout this topic: how an anabolic drug differs from the anti-resorptives you already know, the intermittent-versus-continuous PTH paradox that explains why it works, and how it is used in practice - who gets it, the evidence behind it, the 24-month limit, and the essential follow-on with an anti-resorptive.
Principles: How Teriparatide Builds Bone
Parathyroid hormone is the body's main regulator of calcium. Its effect on the skeleton depends entirely on how the bone is exposed to it, and this is the single most important concept in the topic.
The PTH Paradox - Intermittent vs Continuous
| Feature | Intermittent PTH (teriparatide) | Continuous high PTH (e.g. hyperparathyroidism) |
|---|---|---|
| Exposure pattern | Brief daily pulse from one injection, then levels fall | Persistently elevated hormone all day |
| Dominant cell effect | Favours osteoblast activity and survival - net formation | Drives osteoclast activity through RANKL - net resorption |
| Net skeletal effect | Bone mass and architecture improve (anabolic) | Bone is lost, cortices thin (catabolic) |
| Clinical example | Once-daily teriparatide for osteoporosis | Primary hyperparathyroidism causing osteoporosis and brown tumours |
What happens at the cell level with intermittent dosing:
- A daily injection produces a short spike of PTH that quickly clears.
- This brief pulse acts on osteoblasts (the bone-forming cells) through the PTH/PTHrP receptor, increasing their number and activity and reducing their programmed death.
- The result is a burst of new bone formation that outpaces resorption, so bone mass rises and trabecular architecture is rebuilt - genuinely new bone, not just preserved old bone.
- Because the level falls again between doses, the prolonged signal that would otherwise switch on osteoclasts (through RANKL on osteoblasts) is avoided.
By contrast, when PTH stays high all the time - as in primary hyperparathyroidism - the same receptor signalling sustains RANKL expression, osteoclasts dominate, and bone is steadily resorbed. Same hormone, opposite outcome, decided by the timing of exposure.
This anabolic action also explains the "anabolic window": bone formation rises immediately, while resorption catches up only later, so the early months of treatment give the greatest net gain. Starting with teriparatide before an anti-resorptive (rather than after) tends to make the most of that window.
The Drug in Practice
Teriparatide at a Glance
| Feature | Detail | Why it matters |
|---|---|---|
| What it is | Recombinant human PTH 1-34 | The active fragment of the natural hormone |
| Route and dose | 20 micrograms once daily, subcutaneous | Self-injected, usually into the thigh or abdomen |
| Duration | Maximum 24 months in a lifetime | Driven by the osteosarcoma signal and waning benefit |
| Class | Anabolic (bone-building) | Opposite of the anti-resorptive bisphosphonates and denosumab |
| After stopping | Follow with an anti-resorptive | New bone is lost without a follow-on agent |
A closely related anabolic agent, abaloparatide, is a PTH-related protein analogue with a similar profile. Romosozumab (an anti-sclerostin antibody) is another bone-building option but works by a different mechanism. For the exam, teriparatide is the prototype anabolic drug and the one to discuss by default.
Indications
Teriparatide is reserved for severe or high-risk osteoporosis rather than first-line use, because of its cost, the daily injection, and the duration limit.
Severe Osteoporosis
Postmenopausal women and men with very low bone density or multiple or recurrent fragility fractures, especially vertebral fractures - the group with the most to gain from rebuilding bone.
Treatment Failure
Patients who fracture or keep losing bone despite an anti-resorptive - switching to an anabolic agent that builds bone is a logical next step.
Glucocorticoid-Induced Osteoporosis
High-dose, long-term steroid users at high fracture risk, where teriparatide has shown strong bone-density gains compared with bisphosphonates.
Selected Fracture-Healing Roles
Off-label interest in stalled or fragile fracture healing (for example certain osteoporotic pelvic or atypical femoral fractures and nonunions), supported by smaller studies rather than large trials.
Clinical Relevance
Teriparatide turns up across the exam and orthopaedic practice precisely because it is the odd one out. In basic-science vivas it is the go-to example of an anabolic drug and the home of the intermittent-versus-continuous PTH paradox - a favourite way to test whether a candidate truly understands bone biology rather than memorising drug names. In the fracture and metabolic-bone clinic it is the escalation option for severe osteoporosis and treatment failure, and it forces the candidate to discuss drug sequencing (build then preserve). In trauma, it appears in discussions of atypical femoral fractures and difficult or fragile fracture healing, where its bone-building action is attractive. Knowing what it is, why intermittent dosing matters, who to give it to, and what to do afterwards is the practical core examiners probe.
Evidence for Teriparatide
Teriparatide Reduces Fractures - the Landmark Trial (Neer)
- Randomised trial of 1637 postmenopausal women with prior vertebral fractures, daily PTH 1-34 (20 or 40 micrograms) versus placebo over a median of 21 months
- New vertebral fractures fell from 14 percent on placebo to 5 percent on the 20 microgram dose (relative risk about 0.35)
- New non-vertebral fragility fractures roughly halved (relative risk about 0.47)
- Lumbar spine bone mineral density rose markedly; side effects were minor (occasional nausea and headache)
Teriparatide Beats Risedronate for Vertebral Fracture in Severe Osteoporosis (VERO)
- Double-blind, double-dummy RCT of 1360 postmenopausal women with severe osteoporosis (at least two moderate or one severe vertebral fracture), teriparatide versus risedronate over 24 months
- New vertebral fractures: 5.4 percent with teriparatide versus 12.0 percent with risedronate (risk ratio 0.44)
- Clinical fractures: 4.8 percent versus 9.8 percent (hazard ratio 0.48)
- The first head-to-head trial powered on incident fractures to favour an anabolic over an anti-resorptive agent
Teriparatide Accelerates New Bone Mineralisation (Distraction Osteogenesis RCT)
- Randomised crossover study of 16 patients during the consolidation phase after tibial bone segment transport (distraction osteogenesis)
- Eight weeks of daily subcutaneous teriparatide roughly doubled the rate of bone mineralisation of the regenerate compared with no treatment
- Adjusted analysis showed an additional bone mineral density gain attributable to teriparatide (about 0.19 g per square centimetre, p less than 0.001)
- Provides direct human evidence that teriparatide stimulates new bone formation in a healing setting
Safety, Limits and How It Compares
The 24-month limit and the osteosarcoma signal
Lifelong use is not allowed. Treatment is capped at 24 months because high-dose lifelong teriparatide caused osteosarcoma in rats. Although this has not been borne out as a clinically meaningful risk in humans at therapeutic doses, the limit and the contraindications (Paget disease, prior skeletal radiotherapy, unexplained high alkaline phosphatase, open growth plates, bone metastases or skeletal malignancy) remain in force.
Common, usually minor side effects include nausea, headache, dizziness, leg cramps, and a transient small rise in serum calcium after each dose. Check that the patient is not hypercalcaemic before starting.
Teriparatide vs Bisphosphonates - the Core Contrast
| Feature | Teriparatide | Bisphosphonates |
|---|---|---|
| Drug class | Anabolic - builds bone | Anti-resorptive - slows bone loss |
| Main cell target | Stimulates osteoblasts | Inhibits osteoclasts |
| Administration | Daily subcutaneous injection | Oral weekly or intravenous, intermittently |
| Typical use | Severe or high-risk osteoporosis, treatment failure | First-line for most osteoporosis |
| After stopping | Gains lost unless followed by an anti-resorptive | Effect persists for a time (drug stays bound to bone) |
Clinical Pearl
The sequence matters: build, then preserve. Use teriparatide to add bone, then switch to a bisphosphonate or denosumab to keep it. Stopping teriparatide and giving nothing lets the newly formed bone be resorbed - and stopping denosumab without a follow-on can cause rebound vertebral fractures, so never leave a high-risk patient on no treatment.
Exam Viva Scenarios
Use these scenarios to practise clinical reasoning and management decisions
What Makes Teriparatide Different (~3 min)
"A 71-year-old woman with severe osteoporosis and two vertebral fractures is started on teriparatide after failing a bisphosphonate. The examiner asks what teriparatide is, how it works, and how it differs from the drug she was on."
What it is: Teriparatide is recombinant human parathyroid hormone, the 1-34 fragment - the active N-terminal part of the natural hormone. It is given as a once-daily subcutaneous injection.
How it works: It is an anabolic drug - it builds bone. The key concept is intermittent versus continuous exposure. A short daily pulse of PTH stimulates osteoblasts, increasing bone formation more than resorption, so bone mass and architecture improve. If PTH were continuously high, as in hyperparathyroidism, the same receptor signalling would drive osteoclasts through RANKL and bone would be lost instead.
How it differs: Her bisphosphonate was anti-resorptive - it inhibited osteoclasts to slow bone loss. Teriparatide does the opposite by stimulating bone formation, which is why it is used when an anti-resorptive has failed.
Practical points: It is limited to 24 months, and I would follow it with an anti-resorptive to preserve the bone gained.
Choosing and Sequencing in Severe Osteoporosis (~4 min)
"A 68-year-old man has a new vertebral fracture and a very low bone density T-score despite two years of alendronate. The examiner asks how you would treat him and what cautions apply to teriparatide."
Assessment first: I would confirm this is genuine treatment failure - check adherence and correct administration of the bisphosphonate, and exclude secondary causes such as vitamin D deficiency, hyperparathyroidism, myeloma, and steroid use. I would correct calcium and vitamin D.
Why an anabolic agent: He is high risk with a new fracture on an anti-resorptive, so switching to an anabolic drug that builds bone is logical. Teriparatide reduces vertebral and clinical fractures and, head-to-head, outperformed risedronate in severe osteoporosis.
Cautions before starting: I would exclude contraindications - Paget disease, prior skeletal radiotherapy, unexplained raised alkaline phosphatase, bone metastases or skeletal malignancy, and hypercalcaemia. I would counsel on the daily injection, transient calcium rise, and minor side effects, and explain the 24-month limit.
Sequencing: After up to 24 months I would follow with an anti-resorptive - a bisphosphonate or denosumab - to lock in the bone gained, because the gains are otherwise lost.
TERIPARATIDE
Clinical summary
What It Is
- •Recombinant human PTH 1-34 (the active fragment)
- •Anabolic - the bone-building osteoporosis drug
- •20 micrograms once daily, subcutaneous
- •Opposite of anti-resorptive bisphosphonates
Mechanism
- •Intermittent daily pulse stimulates osteoblasts - bone forms
- •Continuous high PTH drives osteoclasts (RANKL) - bone lost
- •Same hormone, opposite effect, set by exposure pattern
- •Early 'anabolic window' gives the biggest net gain
Use and Evidence
- •For severe or high-risk osteoporosis and treatment failure
- •Neer 2001: new vertebral fractures cut by about two-thirds
- •VERO 2018: beat risedronate for vertebral fracture in severe disease
- •Some evidence for accelerating fragile fracture healing
Limits and Red Flags
- •Maximum 24 months lifetime - osteosarcoma signal in rats
- •Avoid: Paget, prior skeletal radiotherapy, high ALP, open physes, bone cancer
- •Always follow with an anti-resorptive to preserve gains
- •Minor: nausea, headache, leg cramps, transient calcium rise
Guidelines, Registries and Global Practice
- Major osteoporosis guidelines (for example the Endocrine Society, AACE, NOGG in the UK, and bone-health initiatives endorsed by AAOS/AOA) position teriparatide as a treatment for severe or very high fracture-risk osteoporosis and for patients who fracture or lose bone despite an anti-resorptive, rather than as a first-line agent.
- Anabolic-first sequencing is increasingly endorsed for the highest-risk patients (those with recent or multiple vertebral fractures), reflecting head-to-head trial evidence that anabolic therapy reduces vertebral fractures more than oral bisphosphonates in this group.
- Guidance consistently stresses the mandatory follow-on anti-resorptive after stopping teriparatide to preserve bone gained, and the 24-month lifetime limit.
- Global practice variation is driven mainly by cost and access - the daily injection and price mean teriparatide is reserved for selected high-risk patients in most health systems, while the underlying principles (build then preserve, reserve for severe disease) are consistent worldwide.